Jacob Gottlieb is the Managing Partner and Chief Investment Officer of Altium Capital Management. Jacob has over 15 years of hedge fund investing experience and he led a team of more than 85 investment professionals focused primarily on fundamental equity long/short strategies.

Jacob founded Visium in 2005 after working as a Partner and Portfolio Manager at Balyasny Asset Management, LP, where he led a team of more than 20 investment professionals. Prior to Balyasny, Jacob was a Portfolio Manager at Merlin, and began his career as a buy-side equity analyst at Sanford C. Bernstein.

Jacob holds a Bachelor of Arts in Economics from Brown University (magna cum laude) and a medical degree from New York University. He obtained his CFA charter in 2001, and his PRM designation from the Professional Risk Managers' International Association in 2010.

Learn more at: www.jacobgottlieb.com




Joshua Thomas is a Portfolio Manager at Altium Capital Management.  Joshua has over 14 years of hedge fund investing experience, including responsibility for risk management, idea generation, and the development of research processes and trading strategies.  

Prior to Altium, Joshua was the Managing Partner of Midsummer Capital, the investment manager of several hedge funds operating in the small cap sector.  He  oversaw the launch and management of Midsummer Small Cap, an equity long/short product, from 2010 through its wind down in 2016.  Also during his tenure at Midsummer, Joshua served on the board of directors of several portfolio companies, structured and negotiated complex securities, and led both operational and financial restructurings.  

Joshua began his career in various roles in investment banking and equity analysis at Merrill Lynch, ABN Amro and Sanford Bernstein.  During his time in investment banking, he marketed and executed a variety of transactions, including private placements, venture financings, and mergers and acquisitions.  In equity research at Sanford Bernstein, Mr. Thomas covered broadline retailers and helped to launch coverage on the department store sector.

Joshua holds a Bachelor of Arts in Economics from Vanderbilt University (magna cum laude).




Joseph Gulfo has more than 25 years of experience in the biopharmaceutical and medical device industries. Dr. Gulfo served as President, CEO, and Chairman of MELA Sciences until 2013. While at MELA Sciences, he was responsible for effecting an IPO and consummating 11 public financings totaling ~$160 MM and obtaining FDA approval of the MelaFind PMA despite an initial setback, through which he gained national attention. As President & COO of Anthra Pharmaceuticals and Chairman of its UK subsidiary, he was responsible for the 1998 NDA approval of Valstar. Dr. Gulfo was also instrumental in the development of ProstaScint (Cytogen Corporation), a BLA-approved monoclonal antibody for prostate cancer. He was CEO and Chairman of Antigen Express, an immunotherapy and immunodiagnostics company, and led its merger.

In 2012, Dr. Gulfo received the American Business Awards’ Maverick of the Year Award and was an Ernst & Young Entrepreneur of the Year Finalist. He is the author of The Care Quotient: Transforming Business Through People (Post Hill Press, September 2016) and Innovation Breakdown: How the FDA and Wall Street Cripple Medical Advances (Post Hill Press, June 2014). He is also the author of several papers including The Proper Role of the FDA for the 21st Century (The Mercatus Center, 2016), How Can the FDA Foster Greater Resilience in the Medical Marketplace (Niskanen Center, 2018), and Product Approvability Recommendations from FDA Advisory Committees: Inconsistently Sought, Indirectly Obtained (Sage Journals, 2018).  His work has been published in the Wall Street Journal, Forbes, CNBC, US News & World Report, and other national publications. He teaches graduate cancer biology at Seton Hall University.




David Liu joined Altium Capital Management in January 2019. Prior to joining Altium, David was a Senior Analyst at Iguana Healthcare Partners, a long/short equity hedge fund, where he focused on therapeutics. Previously, he was an Equity Research Associate at RBC Capital Markets focusing on US small and mid-cap biotech.

David received a Ph.D in Molecular Biology from Cornell University, and conducted his thesis research in oncology at the Memorial Sloan-Kettering Cancer Center. He graduated from Stanford University with a B.S. in Biological Sciences.




Prior to Altium, Mark was Partner & Chief Administrative Officer of Visium Asset Management. He led development of the firm from inception (successful spin-out of Visium from Balyasny Asset Management), including operations and accounting infrastructure, corporate development, recruiting, and various expansion efforts. Prior to Visium, Mark was on the investment team at Balyasny, primarily focused on negotiating private investments in public companies in development-stage healthcare (biotech, pharmaceuticals, devices). Mark started his career in corporate finance investment banking at UBS.

Mark holds a MBA from Cornell University in Entrepreneurship & Venture Capital and a BA from Vassar College in Economics. He is a CFA charterholder, and a CAIA charterholder. 

Altium Team